Latest news & pressroom
In the CombiGenes pressroom you will find press releases, newsletters, and the latest reports. High resolution images as well as logos are available for use in articles and in newsstands.
Copyright applies to all footage.
News 2021 2021 2020 2019 2018 2017 2016 2015 This week, CombiGene announced the outcome of a rights issue, which was was resolved by the board of directors on 8 March 2021 based on the authorisation from the annual general meeting held on 29 June 2020....read more
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 The information in this press release is not intended for publication, public release or distribution, directly or indirectly, in or into the USA, Canada, Japan, Australia, Hong Kong, New Zealand,...read more
News 2021 2021 2020 2019 2018 2017 2016 2015 Currently, there is no cure for lipodystrophy, and just the secondary complications can be treated. Lipodystrophy is a rare and very serious disease. CombiGene continues to develop the pre-clinical work in the...read more
CG01 project achieves important milestone, initiating preclinical biodistribution and toxicology studies
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene's epilepsy project CG01 is now advancing to the final phase of the preclinical program. Following the release of the material from the first large-scale production of CG01 on March 1,...read more
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 More information (in swedish) >> The information in this press release is not intended for publication, public release or distribution, directly or indirectly, in or into the USA, Canada, Japan,...read more
Find it easy
"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.